drugset / Trial / NCT01898013

Neurosteroids as Novel Therapeutic Agents for Chronic Pain in OEF/OIF Veterans

NCT01898013

Phase 2 Completed 94 enrolled Durham VA Medical Center
RandomizedParallel-groupTriple-blindTreatment

Summary

The study design is a randomized, double-blind, two-arm trial of pregnenolone and placebo to determine the possible analgesic effects in OEF/OIF Veterans with chronic low back pain. The total study duration is 6 weeks (followed by two-follow up phone calls). All patients will monitor pain symptoms for one week with pain diaries, followed by a 1-week placebo-only lead-in period, 90 subjects will be randomly assigned to one of two groups. Of these subjects, 45 subjects will receive pregnenolone, and 45 subjects will receive placebo for 4 weeks. Patient interview assessments and laboratory studies will be performed at each interview time point. Pregnenolone, allopregnanolone and other neurosteroid metabolites will be determined by gas chromatography / mass spectrometry (GC/MS), proceeded by high performance liquid chromatography (HPLC).

Timeline

Start
2013-09-13
Primary completion
2017-04-03
Completion
2017-04-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pregnenolone Other / unclassified 250 mg Oral

Indications

No indication recorded.